CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) - USD ($)		3 Months Ended
		Mar. 31, 2026	Mar. 31, 2025
Income Statement [Abstract]
Product Revenues – net of Discounts and Rebates		$ 162,092	$ 163,552
Cost of Revenues		85,715	73,272
Gross Profit		76,377	90,280
Research Revenues			92,731
Net Revenue		76,377	183,011
Operating Expenses:
Research and Development		281,464	370,813
General and Administrative Expenses		1,889,874	1,723,136
Total Operating Expenses		2,171,338	2,093,949
Loss from Operations		(2,094,961)	(1,910,938)
Interest Expense		(1,389)	(1,790)
Change in Fair Value of Derivative Liabilities		(4,567)	5,105
Other Income, net		10,762	30,322
Total Interest and Other Income, net		4,806	33,637
Loss from Operations before Provision for Income Taxes		(2,090,155)	(1,877,301)
Provision for Income Taxes (Note 9)
Net Loss including Noncontrolling Interest		(2,090,155)	(1,877,301)
Net Loss – Noncontrolling Interest		(941)	(752)
Net Loss – attributed to 60 Degrees Pharmaceuticals, Inc.		(2,089,214)	(1,876,549)
Comprehensive Loss:
Net Loss		(2,090,155)	(1,877,301)
Unrealized Foreign Currency Translation Gain (Loss)		5,942	(9,904)
Total Comprehensive Loss		(2,084,213)	(1,887,205)
Net Loss – Noncontrolling Interest		(941)	(752)
Comprehensive Loss – attributed to 60 Degrees Pharmaceuticals, Inc.		(2,083,272)	(1,886,453)
Cumulative Dividends on Series A Preferred Stock		(125,312)	(118,158)
Net Loss - attributed to common stockholders		$ (2,208,584)	$ (2,004,611)
Net Loss per Common Share:
Basic (in Dollars per share)	[1]	$ (1.28)	$ (6.25)
Diluted (in Dollars per share)	[1]	$ (1.28)	$ (6.25)
Weighted Average Number of Common Shares Outstanding
Basic (in Shares)	[1]	1,725,758	320,890
Diluted (in Shares)	[1]	1,725,758	320,890

[1] Prior periods presented have been adjusted to reflect the 1:4 reverse stock split on January 20, 2026.